We compared the efficacy of adalimumab, infliximab, ustekinumab, and vedolizumab on the ability to achieve endoscopic healing (EH) after one-year of therapy in moderate-severe Crohn's disease (CD). Pooled analysis of patient-level data from 299 patients with CD from four clinical trials. Proportions of patients treated with each biologic were compared for achieving one-year complete endoscopic healing (EH) (SES-CD<3), and ileal and colonic EH separately (SES-CD=0). Multivariate logistic regression was used to model the relationship between biologics and one-year outcomes, adjusted for disease duration, concomitant corticosteroid use, and prior anti-TNF failure. Compared to vedolizumab 4/56 (7.1%), adalimumab 17/61 (27.9%), aOR: 5.79 (95% CI: 1.77-18.95), p=0.004 and infliximab 39/141 (27.7%), aOR: 4.59 (95% CI: 1.48-14.22), p=0.008 had superior rates of one-year EH. No significant difference was observed between vedolizumab and ustekinumab. Similar results were observed among biologic-naïve patients. Among patients with baseline ileal SES-CD ≥3, no significant differences were observed between biologics for one-year ileal EH. However for large (>0.5cm) ileal ulcers, infliximab 20/49 (40.8%) had superior rates of no ileal ulcers compared to vedolizumab 2/23 (8.7%), aOR: 5.39 (95% CI: 1.03-28.05), p=0.045. No other differences were observed. For colonic disease, compared to ustekinumab 9/31 (29.0%), adalimumab 30/48 (62.5%), aOR: 3.97 (95% CI: 1.45-10.90), p=0.007 had superior rates of one-year EH in the colon, with similar trends observed for infliximab (55/105 (52.4%), aOR: 2.08 (95% CI: 0.82-5.27), p=0.121. No other differences were observed. In this post-hoc analysis, TNFα antagonists were overall superior to vedolizumab and ustekinumab for achieving one-year EH in moderate-severe CD patients.